Document text
Principal Investigator: MICHAEL DAVID ALPERT
Organization: EMMUNE, INC
Fiscal Year: 2023
Award: $1,000,000
Funding agency: National Institute of Allergy and Infectious Diseases
We are developing vaccine antigens for SARS-CoV-2 that focus the antibody response onto neutralizing epitopes in the receptor binding domain (RBD) of the viral Spike (S) protein. Booster antigens derived from variants of SARS-CoV-2 would especially benefit from being limited to the RBD, due to the preponderance of conserved but non-neutralizing epitopes in the full-length S protein. However, RBD-only vaccines face the technical limitations of aggregation and poor expression, due to hydrophobic patches on the RBD that form the inter-subunit interfaces in the native S protein. We have overcome these limitations by engineering N- linked glycosylation sites into the RBD. These glycans also help to focus the immune response away from off-target faces of the RBD, and onto the targets for potent neutralizing antibody responses. We will extend this strategy further, to focus the antibody response onto neutralizing epitopes in the RBD that are conserved among variants of SARS-CoV-2. The RBD antigens will be tested as lipid nanoparticle (LNP)-mRNA vaccines. In Phase I of this project, we will enhance the intrinsic immunogenicity of RBD antigens delivered as LNP-mRNA vaccines. In Phase II, we will build upon this platform to compare boosters based on variant- derived RBD versus variant-derived full-length S, and to optimize RBD antigens for focusing antibody responses onto neutralizing epitopes that are conserved among variants of SARS-CoV-2. The antigens generated by this project will exploit four levels of immunofocusing to elicit or boost antibody responses that recognize conserved epitopes in the RBD and neutralize antigenically-distinct variants of SARS-CoV-2.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><Address><Antibody Response><Antibody titer measurement><Antigenic Determinants><Antigens><B cell receptor><B-Cell Antigen Receptor><Binding Determinants><COVID-19 antigen><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19 vaccine><COVID19 virus><Cell Body><Cells><CoV-2><CoV2><Collaborations><Communities><Cytoplasmic Domain><Cytoplasmic Tail><Data><Engineering><Engraftment><Epitopes><Face><Future><Glycans><Goals><Golden Hamsters><Golden Syrian Hamsters><Grant><Human><Hydrophobicity><Immune response><Immunological response><In Vitro><Length><Link><Lymphoid><Mann-Whitney U Test><Mesocricetus auratus><Messenger RNA><Metabolic Glycosylation><Modern Man><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Muscle><Muscle Tissue><Phase><Polysaccharides><Population><Position><Positioning Attribute><Primates><Primates Mammals><Protein Subunits><Proteins><RNA vaccine><RNA-based vaccine><Research><Rodent><Rodentia><Rodents Mammals><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antigen><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 antigen><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Syrian Hamsters><TM Domain><Tail><Testing><Transfection><Transmembrane Domain><Transmembrane Region><Vaccine Antigen><Vaccines><Variant><Variation><Viral><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><antibody titering><corona virus disease 2019 vaccine><coronavirus disease 2019 antigen><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><crosslink><design><designing><develop a vaccine><develop vaccines><development of a vaccine><exosome><experiment><experimental research><experimental study><experiments><faces><facial><glycosylation><hCoV19><host response><immune system response><immunogen><immunogenic><immunogenicity><immunoresponse><improved><industrial partnership><industry partner><industry partnership><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><muscular><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><nano particle delivery><nanoparticle delivered><nanoparticle delivery><neutralizing antibody><public health relevance><receptor binding><receptor bound><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine development><vaccine efficacy><vaccine for novel coronavirus><variants of concern>